share_log

8-K/A: Executive Employment Agreement (Amendment)

8-K/A: Executive Employment Agreement (Amendment)

8-K/A:高管聘用协议(修正)
美股SEC公告 ·  10/01 16:11

Moomoo AI 已提取核心信息

Cassava Sciences, Inc., a biopharmaceutical company, has filed an amendment to its original Form 8-K report with the SEC, detailing the compensation terms for its newly appointed CEO, Richard Barry. The amendment, dated October 1, 2024, follows the initial announcement on September 9, 2024, which did not include these details. Barry's appointment as CEO was effective as of September 6, 2024. The Board approved an executive employment agreement that includes an initial base salary of $675,000 retroactive to July 15, 2024, a target annual bonus of 60% of his base salary, and a stock option award to purchase 600,000 shares at $27.42 per share. The options will vest over four years, contingent upon Barry's continued employment. Additionally, the agreement outlines severance benefits in the event of termination without cause or resignation for good reason, including a year's base salary and medical plan coverage. The full terms of the Employment Agreement are detailed in Exhibit 10.1 attached to the amendment.
Cassava Sciences, Inc., a biopharmaceutical company, has filed an amendment to its original Form 8-K report with the SEC, detailing the compensation terms for its newly appointed CEO, Richard Barry. The amendment, dated October 1, 2024, follows the initial announcement on September 9, 2024, which did not include these details. Barry's appointment as CEO was effective as of September 6, 2024. The Board approved an executive employment agreement that includes an initial base salary of $675,000 retroactive to July 15, 2024, a target annual bonus of 60% of his base salary, and a stock option award to purchase 600,000 shares at $27.42 per share. The options will vest over four years, contingent upon Barry's continued employment. Additionally, the agreement outlines severance benefits in the event of termination without cause or resignation for good reason, including a year's base salary and medical plan coverage. The full terms of the Employment Agreement are detailed in Exhibit 10.1 attached to the amendment.
Cassava Sciences公司是一家生物制药公司,已向美国证券交易委员会提交了原始8-k表格报告的修正版本,详细说明了新任CEO Richard Barry的薪酬条款。这项修正日期为2024年10月1日,是在2024年9月9日的初始公告之后,该公告未包括这些细节。Barry作为CEO的任命自2024年9月6日生效。董事会批准了一项高管雇佣协议,包括从2024年7月15日起追溯的初始基本工资为67.5万美元,目标年度奖金为其基本工资的60%,以及以每股27.42美元购买60万股的期权奖励。这些期权将在四年内按照Barry的继续工作而行使。此外,协议概述了因无故解雇或由于正当理由辞职而终止的离职福利,包括一年的基本工资和医疗保险。雇佣协议的全部条款在修正版附加的10.1附件中详细说明。
Cassava Sciences公司是一家生物制药公司,已向美国证券交易委员会提交了原始8-k表格报告的修正版本,详细说明了新任CEO Richard Barry的薪酬条款。这项修正日期为2024年10月1日,是在2024年9月9日的初始公告之后,该公告未包括这些细节。Barry作为CEO的任命自2024年9月6日生效。董事会批准了一项高管雇佣协议,包括从2024年7月15日起追溯的初始基本工资为67.5万美元,目标年度奖金为其基本工资的60%,以及以每股27.42美元购买60万股的期权奖励。这些期权将在四年内按照Barry的继续工作而行使。此外,协议概述了因无故解雇或由于正当理由辞职而终止的离职福利,包括一年的基本工资和医疗保险。雇佣协议的全部条款在修正版附加的10.1附件中详细说明。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息